Regeneron Pharmaceuticals stock (US75811P1003): shares steady near 52-week low

Regeneron Pharmaceuticals shares were near $627.74 on 05/28/2026 in Nasdaq trading, while a Thursday sector module adds context on valuation and positioning.

Regeneron Pharmaceuticals shares changed hands at $627.74 on 05/28/2026 on Nasdaq, according to Robinhood as of 05/28/2026. The move leaves the stock well below its 52-week high of $821.11 and only modestly above the 52-week low of $476.79, while a separate market snapshot put volume at 1.91 million shares on the day.

In the United States, where Regeneron is listed on Nasdaq, the latest quote places the biotech group close to the lower end of its one-year range, with the same-day trading data showing a market-cap-sized company under pressure after earlier volatility in May. On 05/28/2026, a second market snapshot also showed the stock at $633.71 at the open, with a previous close of $634.62, high of $637.78 and low of $625.80, underscoring a narrow trading band in home-market dealing.

As of: 05/28/2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: REGN
• Sector/industry: Biotechnology
• Headquarters/country: Tarrytown, United States
• Core markets: United States, Europe, and other international markets
• Key revenue drivers: Ophthalmology, immunology, oncology, and other medicines
• Home exchange/listing venue: Nasdaq (REGN)
• Trading currency: USD

Regeneron Pharmaceuticals: core business model

Regeneron develops, manufactures, and commercializes medicines for serious diseases, with revenue tied mainly to specialty therapies across eye disease, inflammation, cancer, cardiovascular and metabolic conditions, infection, pain, and rare diseases.

Industry trends and competitive position

Regeneron remains in a competitive U.S. biotech market where valuation often reflects pipeline expectations, product mix, and pricing power rather than near-term earnings alone. A valuation snapshot from Simply Wall St put the stock at US$833.31 fair value and described it as 23.8% undervalued, while also noting an analyst forecast that was more than 20% above the current share price on 05/28/2026.

That same market backdrop is visible in public quote data: Robinhood showed a price-to-earnings ratio of 15.46 on 05/28/2026, and Moneycontrol described the company as a biotechnology business focused on medicines for serious diseases. For a Nasdaq-listed U.S. company, that combination of lower-than-fair-value screens and a moderate earnings multiple points to a market still weighing growth durability against broader biotech sentiment.

Additional news and developments on the stock can be explored via the linked overview pages.

Conclusion

Regeneron’s Nasdaq trading profile on 05/28/2026 suggests investors are still focused on the balance between valuation support and market caution around biotech execution. Thursday’s sector view adds a second lens: the stock is being measured not just by price action, but by how its earnings multiple and fair-value estimates compare with the market’s current discount.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.